SUNNYVALE, Calif. , March 28, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the appointment of Emad Rizk , M.D. to the company's Board of Directors, effective March 15, 2013 . Dr. Rizk is a renowned healthcare industry expert who brings more than 25 years of experience
Hong Kong Adventist Oncology Center Offers Full Spectrum of Disease Treatment with State-of-the-art Technologies SUNNYVALE, Calif. , March 11, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Hong Kong Adventist Oncology Center , the first center locally to offer both
SUNNYVALE, California , March 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY ), today announced highlights from the First European Conference on stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and image-guided intensity-modulated radiation therapy (IG-IMRT),
SUNNYVALE, Calif. , Feb. 26, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Cowen and Company Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 9:20 a.m. EST / 6:20 a.m.
SUNNYVALE, Calif. , Feb. 11, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that its president and chief executive officer, Joshua H. Levine , is scheduled to present at the Leerink Swan Global Healthcare Conference in New York on Thursday, February 14, 2013 at 9:20 a.m.
SUNNYVALE, Calif. , Feb. 8, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) (" Accuray ") today announced the pricing of its offering of $100 million aggregate principal amount of 3.50% convertible senior notes due 2018 (the "notes"). The notes are being offered and sold to qualified
SUNNYVALE, Calif. , Feb. 6, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) (" Accuray ") today announced its intention to commence an offering, subject to market and other conditions, of $75 million aggregate principal amount of convertible senior notes due 2018 (the "notes"), to be
Decline in Product Revenue Partly Offset by Strong Service Revenue and Profitability SUNNYVALE, Calif. , Feb. 6, 2013 /PRNewswire/ -- Accuray Incorporated , a radiation oncology company, (Nasdaq: ARAY) today announced financial results for the second quarter of fiscal 2013 that ended December 31,
European CyberKnife Center to Offer Patients Advanced Radiosurgery Treatments in Munich SUNNYVALE, Calif. , Feb. 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a radiation oncology company, announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) has treated the
SUNNYVALE, Calif. , Jan. 17, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its second quarter of fiscal 2013, ended December 31, 2012 on Wednesday, February 6, 2013 after the market closes.
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
